Share This Author
Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid…
- B. Cheson, J. Bennett, C. Bloomfield
- MedicineJournal of clinical oncology : official journal…
- 15 December 2003
An International Working Group met to revise the diagnostic and response criteria for acute myelogenous leukemia, as well as to provide definitions of outcomes and reporting standards to improve interpretability of data and comparisons among trials.
Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies.
Analysis of the mutation of D835 of FLT3, which corresponds to D816 of c-KIT, in a large series of human hematologic malignancies demonstrates that the FLT 3 gene is the target most frequently mutated to become constitutively active in AML.
Prognostic implication of FLT3 and N-RAS gene mutations in acute myeloid leukemia.
The FLT3 gene mutation, whose presence is detectable only by genomic polymerase chain reaction amplification and gel electrophoresis, might serve as an important molecular marker to predict the prognosis of patients with AML.
Efficacy and safety of recombinant human soluble thrombomodulin (ART‐123) in disseminated intravascular coagulation: results of a phase III, randomized, double‐blind clinical trial
When compared with heparin therapy, ART‐123 therapy more significantly improves DIC and alleviates bleeding symptoms in DIC patients.
High complete remission rate and promising outcome by combination of imatinib and chemotherapy for newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia: a phase II study by the Japan Adult…
- M. Yanada, J. Takeuchi, R. Ohno
- Medicine, BiologyJournal of clinical oncology : official journal…
- 20 January 2006
The results demonstrated that imatinib-combined regimen is effective and feasible for newly diagnosed BCR-ABL-positive ALL, and a major potential of this treatment is recognized.
Biologic and clinical significance of the FLT3 transcript level in acute myeloid leukemia.
Overexpression of FLT3 (more than 200,000 copies/microgRNA) was an unfavorable prognostic factor for overall survival in 91 AML cases withoutFLT3/ITD and indicated that FLT1 overexpression may distinguish a novel disease entity in AML without FLT 3 mutations and serve as a therapeutic target for FLT2 inhibitors.
Analysis of genetic polymorphism in NQO1, GST-M1, GST-T1, and CYP3A4 in 469 Japanese patients with therapy-related leukemia/ myelodysplastic syndrome and de novo acute myeloid leukemia.
- T. Naoe, K. Takeyama, R. Ohno
- Biology, MedicineClinical cancer research : an official journal of…
- 1 October 2000
Results suggest that the NQOJ polymorphism is significantly associated with the genetic risk of TRLIMDS, and the incidence of homologous deletion was similar among the three groups.
Establishment of a novel human megakaryoblastic leukemia cell line, MEG-01, with positive Philadelphia chromosome.
This novel human megakaryoblastic cell line was established from the bone marrow of a patient with blast crisis of Philadelphia (Ph1) chromosome-positive chronic myelogenous leukemia and may provide a useful model for the study of humanMegakaryopoiesis and of the biosynthetic mechanisms of proteins unique tomegakaryocytic lineage.
Internal tandem duplication of FLT3 associated with leukocytosis in acute promyelocytic leukemia
Clinically, the presence of FLT3/ITD was related to high peripheral white blood cell counts as well as peripheral leukemia cell counts, and high ldh level, and low fibrinogen concentration, suggesting that FLT 3/ ITD plays a significant role in progression of APL.
Induction therapy by frequent administration of doxorubicin with four other drugs, followed by intensive consolidation and maintenance therapy for adult acute lymphoblastic leukemia: the JALSG-ALL93…
In order to improve the disappointing prognosis of adult patients with acute lymphoblastic leukemia, similar induction therapy as that used for acute myeloid leukemia (AML), ie frequent administration of doxorubicin (DOX), was applied, and Ph-negative chromosome was a common favorable prognostic factor for CR, longer OS and DFS.